CARDIUM™ THERAPEUTICS

New and Innovative Products for Today and Tomorrow

Investor Fact Sheet

Cardium is a medical technology company focusing on innovative products for treating cardiovascular and related indications that are leading healthcare priorities. We are in the process of building a business that balances products for "today" that are either currently marketed or have advanced to near-term sales or partnering opportunities, as well as breakthrough products for "tomorrow." We are assembling a portfolio of forward-focused therapeutic biologics and medical devices designed to transform the practice of medicine. They each have well-defined commercial pathways and represent substantial economic opportunities. While varied in approach, our portfolio is uniformly directed to the prevention and treatment of ischemic injuries. Our biologics and medical devices are designed to leverage the human body's natural capacity to heal, protect and repair. The products in our portfolio are designed for one-time application to heal and repair the underlying medical condition or to prevent further injury in acute or surgical settings. As our products and product candidates are successfully advanced, we intend to continue to pursue opportunistic acquisitions designed to enhance long-term stockholder value.

As an emerging public company, we have initially focused on acquiring undervalued opportunities having unrealized value but which we believe have potential for significant future growth and development or partnering prospects when combined with the value-added skills and perspectives of our experienced management team. As a result of this strategy, since Cardium's inital funding in October 2005, we have completed three acquisitions of late-stage clinical product candidates and products with FDA clearance. Over $270 million has been invested by big pharma and venture/ instutional investors for the development of product opportunity and technology that we now control. We plan to continue to build our business through internal development and external acquisitions.

As our current product candidates become sucessfully advanced, we intend to continue to pursue opportunistic acquisitions designed to enhance long-term stockholder value. At the same time, as technologies and product candidates are advanced and businesses are built-up, further developed and mature, we may consider various corporate development transactions to enhance and monetize stockholder value such as corporate partnerings and equity distributions.

We recently announced the acceleration of Generx to a Phase 3 clinical trial based on results from a by-patient meta-analysis of pooled data from the previously conducted clinical studies, which were reviewed with the FDA. Generx represents a new therapeutic class of biologics designed to promote angiogenesis, a natural process of blood vessel growth within the heart muscle, following a one-time intracoronary administration from a standard cardiac infusion catheter.

Stock Symbol:
OTC BB: CDTP

Capitalization:
Outstanding: 32 Million
Float: 21.4 Million
CUSIP: 141916106

Recent Stock Price (01.27.07):
$3.01

Market Capitalization:
$95 Million

Corporate Office:
3611 Valley Centre Drive
Suite 525
San Diego, CA 92130 USA
Tel: 858-436-1000
Fax: 858-436-1001

Email:
investorrelations@cardiumthx.com

Websites:
www.cardiumthx.com
www.innercool.com
www.t-r-co.com

Generx - Phase 3 Product Candidate:



Enhancing the Growth of Microvascular Circulation for Patients with Recurrent Angina

Generx™ - Phase 3 (alferminogene tadenovec)

Generx, our lead product candidate, is the first and only DNA-based cardiovascular therapeutic to be advanced to Phase 3, and is believed to be the only current Phase 3 product candidate for the potential treatment of stable angina, a chronic medical condition affecting millions of patients in the U.S. and elsewhere. Generx is a DNA-based, myocardial-derived growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. Angina, which is often felt as severe chest pain, can significantly limit patients' mobility and quality of life and is a disorder that affects millions of adults in the United States and elsewhere. This Phase 3 clinical study (AWARE), which is expected to be underway in the first quarter of 2007, will be a randomized, placebo-controlled, double-blind trial in approximately 300 women at multiple medical centers in the U.S.

Excellarate™ (PDGF-B) - Phase 2

Excellarate is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate is initially being developed to be administered once or twice for the treatment of non-healing, neuropathic diabetic foot ulcers. The Excellarate topical gel, a type of Gene Activated Matrix™(GAM), is designed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of chemotactic cells such as monocytes and fibroblasts, which are necessary for the stimulation of a variety of wound healing processes. Based on the Phase 1/2 trial, over 80% of the patients who completed the treatment protocol and follow-up exhibited complete closure of previous non-healing wounds by 14 weeks. Excellarate is being advanced to a Phase 2b clinical trial in patients with diabetic foot ulcers in the second half of 2007.

Celsius Control System™

The Celsius Control™ System is designed to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. InnerCool's approach to therapeutic hypothermia is based on a single-use flexible metallic catheter and a fully-integrated endovascular cooling system, which allows for rapid and controlled cooling and re-warming. The Celsius Control System has received FDA 510(k) clearance for use in inducing, maintaining and reversing mild hypothermia in neurosurgical patients, both in surgery and in recovery or intensive care. The system has also received FDA clearance for use in cardiac patients in order to achieve or maintain normal body temperatures during surgery and in recovery / intensive care, and as an adjunctive treatment for fever control in patients with cerebral infarction and intracerebral hemorrhage.

Three Acquisitions Since Initial Funding in 4Q/2005

Business	Therapeutic Application	Clinical / Commercial Status	Disease Focus
Cardium Biologics	Cardiovascular Growth Factors *Generx™*	Initiating Phase 3 Clinical Study 1Q/07	Heart Disease and Angina
InnerCool Therapies	Endovascular Temperature Control *Celsius Control System™*	FDA (510k) Clearance – Marketed & Sold in U.S.	Fever Control & Neurosurgery Research for Heart Attack, Stroke & Cardiac Arrest
Tissue Repair Company	Growth Factor Activated Matrix *Excellarate™*	Initiating Phase 2b Clinical Study 2H/07	Diabetic Foot Ulcers and Tissue Injuries